E56-C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy- Dr. Kourous Rezaei

Dr. Kourous Rezaei reviews the results of the GATHER1 trial on complement C5 inhibition for slowing down progression of geography atrophy in dry AMD. References article: Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. doi: 10.1016/j.ophtha.2020.08.027. Epub 2020 Sep 1. PMID: 32882310.